InnoCare Pharma Ltd. Class A

INNOCARE PHARMA LTD.'s next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2024, INNOCARE PHARMA LTD. has 4.43B shares outstanding.

As of June 30, 2024, INNOCARE PHARMA LTD. maintains a current ratio of 3.82, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.00, indicating elevated leverage, while an interest coverage ratio of -25.97 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2024, INNOCARE PHARMA LTD. posted a negative return on equity (ROE) of -6.55, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.74, reflecting losses generated across the asset base. The company generates approximately 102,176.76 in revenue per employee across its workforce of 1,051.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.99 indicates how many times INNOCARE PHARMA LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, INNOCARE PHARMA LTD. recorded 200,228.44 in income tax expense. The company reported a pretax loss of -66.46M and -64.80M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 13, 2026, INNOCARE PHARMA LTD.'s stock has declined approximately 50.92% over the past 52 weeks.

Over the twelve months ended June 30, 2024, INNOCARE PHARMA LTD. generated 107.44M in revenue and converted that into -64.80M in net income, yielding earnings per share of -0.03. EBITDA reached -89.89M, while operating income came in at -88.37M.

As of June 30, 2024, INNOCARE PHARMA LTD. holds 1.04B in cash and equivalents against 190.96M in total debt, resulting in a net debt position of -769.26M. Total book value stands at 951.15M, with working capital of 820.05M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, INNOCARE PHARMA LTD. posted a gross margin of 85.59, reflecting its pricing power and cost economics. The operating margin of -82.26 and net profit margin of -60.31 provide insight into operational efficiency.

Over the twelve months ended June 30, 2024, INNOCARE PHARMA LTD. paid dividends of 0.00 per share. The dividend payout ratio of -0.06 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.